Dear Mr. Dundler:
As directed by Prof. Basie von Solms, I am herewith sending the following
attachment to be distributed to TC Chairs before they leave for
Toulouse....
_________________________________
Dear TC Chairs:
Please find the revised version, by Prof. Roode, of the International
Federation for Information Processing Guidelines for Responsibilities of
National Representatives to IFIP Technical Committees for discussion in
Toulouse.
Gus Olling
TC5 Chair
========================================================
PAIN MANAGEMENT 2004 - Analysing Regulatory, Commercial
& Pharmaceutical Practices
8th and 9th September 2004 (Workshop 7th September 2004)
Marriott Kensington Hotel, London
========================================================
**FULL AGENDA BELOW** - PDF COPY OF THE BROCHURE NOW AVAILABLE
Visiongain b2b Conferences is pleased to announce that 'Pain Management 2004 - Analysing Regulatory, Commercial & Pharmaceutical Practices ' will be run in early September this year. This event will follow up on the success of 'Future Pain Drugs 2003' but as a case-study based event will focus more on future targets and market development. The agenda is now complete, a list of confirmed speakers and topics can be found below.
KEY THEMES:
- Identify Key Market Segments and Profit From Emerging Trends in Pain Therapeutics
- Clinical Models for Pain- Learn Which Will Suit Your Company Needs
- Discover How Drug Delivery Systems will Shape the Future of Pain Therapeutics, Highlighting Lucrative Market Opportunities
- Learn From the Best Practice Case Studies such as: Actiq- SPM 927- GPI 5693- Imitrax- Tramadol - Buprenorphine- Sativex
- Examine the Key Legal and Regulatory Issues in the Development of Novel Pain Therpaeutics
- Assess the Advances in Cannabis Based Medicines- R&D and Delivery Technologies
- Advice on Scheduling of Centrally Acting Analgesics
CONFIRMED SPEAKERS
**Dr. Peter McIntyre, Lab Head/ Head of Exploratory Pain Projects, Novartis
**Dr. Sharon Bingham, Somatic Pain - Pain Research, Neurology CEDD, GlaxoSmithKline
**Gary Liversidge, Senior Director, Project Planning and Management, Elan
**Praveen Anand, Professor Clinical Neurology, Imperial College
**Dr. Stuart Bevan, Director, Novartis Institute for Medical Research
**Dr. Jeffry Vaught, Senior Vice President & President, R&D Division, Cephalon
**Dr. Christine Rauschkolb, Program Director/ Medical Scientist Pain, Schwarz Bioscience
**Dr. Tony Ho, Associate Director, Merck
**Dr Mike Reed, Director Branded Product Marketing International, Alpharma
**Dr. Krystyna Wozniak, Lead Scientist on NAALADase program, Guilford Pharmaceuticals Inc
**Dr. Stephen Wright, Director of R&D, GW Pharma Ltd
**Dr. Francesco Impagnatiello, Pharmacologist- Pain Research, NicOx
WHO SHOULD ATTEND
-Medical Director
-Divisional VP, Neurological & Urological
-Pain, Migraine Research
-Divisional VP, Immunosciences Development
-Inflammatory Therapeutics
-Respiratory RA Disease Group
-Head of clinical development/ VP clinical development
-Head of clinical research, CNS
-Head of R&D (Pain/CNS/Depression)
-CNS clinical project management
-Head of CNS therapeutics
-Chief Technical Officer
-Director, Preclinical R&D
-Vice President, Research
-Vice President, Research and Development
2003's TESTIMONIALS
"interesting topics, well organised"
"excellent conference"
"very good, covering a wide aspect of pain therapy"
"topline overview of the field"
"topical + scientifically sound"
"exceeded expectations, high scientific level"
---------------------
DELEGATE REGISTRATION
---------------------
Places at this event are limited, please call or email me now to secure your place
- PRICING -
Attend the:
** Conf. + pre conf. workshop GBP 1600.00 Plus VAT
** Conference only Fee: GBP 1299.00 Plus VAT
** Pre conference workshop only Fee: GBP 650.00 Plus VAT
- BOOKINGS -
Booking is easy, simply contact Joe Stone on:
Telephone: +44 (0)20 8767 6711
Fax: +44 (0)20 8767 5001
Email: mailto:joe.stone@visiongain.com
Terms and conditions apply - see below.
Kind regards,
Joe Stone
Account Manager
Visiongain b2b Conferences
Tel: +44 (0) 20 8767 6711
http://www.b2b-conferences.com
mailto:Joe.stone@visiongain.com
==============================================================================================
-----------------
** FULL AGENDA **
-----------------
PRE-CONFERENCE INTERACTIVE WORKSHOP - Tuesday 7th September 2004
LifeSpan Biosciences: The Pathology of Pain
Led by: Dr. Julian Beesley, VP European Sales & Business Development, LifeSpan Biosciences, Inc
-Molecular pathology approach and studies at LifeSpan
-Industrialization of the molecular pathology process
-Drug targets, selection of targets and receptor localisation
-Automated Lifespan Imaging and Analysis System (ALIAS)
=====================================
Day One Wednesday 8 th September 2004
=====================================
09:00 Registration and coffee
09:30 Opening remarks from the Chair
MODELS AND TARGETS
09:40 Developments in Pain Therapy- Ventures for Your
Company
* Molecular targets in pain research- past, present and future
* Research methodologies- how can you implement them?
* Research tools and how best to use them
* Balancing risk in the research portfolio - gain positive results
for your company
* Outlook: new targets for pain relief ligands and the future for
pain therapies in the clinic
Dr. Peter McIntyre
Lab Head/ Head of Exploratory Pain Projects
Novartis
10:20 Human Pain Models- How Can You Maximise Their Use?
* Limitations of current animal models- find how they relate to
human data
* Clinical needs- pathophysiological and imaging surrogates
* Lessons to learn from failed clinical trials- gain knowledge on
avoiding and overcoming similar problems
* How to increase the success of Phase II clinical trials
* Target validation: novel pain targets in human chronic states
* How to select patients for successful POC clinical trials
* New models for assessing pain- examples and how to
implement them
Praveen Anand
Professor Clinical Neurology
Imperial College
11:00 Morning Coffee
11:20 How to Use Nitric Oxide (NO) Properties to Achieve Effective Therapeutics
* NO-releasing analgesics: a novel class of drugs for the treatment of pain
* The contribution of NO-releasing moiety to commonly-used analgesics: rationale and potential added values
* Case studies: NO-releasing paracetamol/NO-releasing gabapentin
* Potential mechanisms of action of NO in pain/inflammation
Dr. Francesco Impagnatiello
Pharmacologist- Pain Research
NicOx
12:00 Find New Targets and Pointers to Validate them
* Pain signalling pathways- where can you find new targets?
* Pharmacological mechanisms of pain
* Pain platforms- detailing the molecular basis
* Target validation- strategies for success
* Target identification vs target validation
* Target treatment- is there a need and future ventures for your
company
Dr. Ray Scraggs
Pharmaceutical Consultant
visiongain Consultancy
12:40 Lunch
14:00 Using Animals- How to make them Disease Relevant
Pain Models?
* Classical versus novel approaches to pain models- what will
suit your needs?
* Changing views on behavioural versus functional endpoints
* How you can validate a model- pointers
* Difficulties in assessing pain in animals- how effective are
these models and how to improve them
* Screening putative analgesics
* How to use animal models for causes of pain
Dr. Sharon Bingham
Somatic Pain - Pain Research
Neurology CEDD
GlaxoSmithKline
14:40 The Role of Vanilloid Receptors in Nociception
* Expression of vanilloid receptors
- how to demonstrate the existence of specific vanilloid
receptors
* Molecular and functional characterisation of cloned VR1
* VR1 as a pivotal transducer
* Comparison of VR1 and native receptors- what advantaged
can you make use of?
Dr. Stuart Bevan
Director
Novartis Institute for Medical Research
15:20 Afternoon Tea
15:40 Advice on Scheduling of centrally acting analgesics
* The rationale of scheduling- how and why?
* International and national conventions and laws- what to
foresee as a result
* Development and registration of controlled drugs
* Marketing of controlled drugs- recommendations
* Case Studies: Tramadol and buprenorphine
Dr. Franz Philipp Gerstheimer
Corporate Medical and Scientific Services
Grunenthal GmbH
OVERCOMING CANCER PAIN
16:20 CASE STUDY: Actiq, the only FDA Approved Drug for
Breakthrough Cancer Pain
* Temporal characteristics of persistence and breakthrough pain
* Actiq's novel oral transmucosal system- how does it work?
* Parmacokinetics and pharmacodynamics of oral transmucosal
fentanyl delivery
* What are the benefits of oral transmucosal delivery?
* Onset of action and duration of effect
* Side effects and how you can overcome them
Dr. Jeffry Vaught
Senior Vice President & President, R&D Division
Cephalon
17:00 Questions and Discussion
17:20 Summation of day one from conference chair
====================================
Day Two Thursday 9 th September 2004
====================================
09:00 Registration and Coffee
09:30 Opening remarks from the Chair
NEUROPATHIC PAIN MARKET
09:40 CASE STUDY: Pharmacology of SPM 927 and its
Relevance to Clinical Practice
* Basic pharmacology of SPM 927
* Efficacy of SPM 927 in an animal model for diabetic
neuropathy
* Pharmacological profiling in further animal models for chronic
pain- what can you impliment in practice?
* This anti-convulsant drug's mechanism of action
Dr. Bettina Beyreuther
Senior Scientist Pharmacology- Preclinical Development
Schwarz BioSciences
10:20 CASE STUDY: SPM 927 - A Novel Promising Pain Treatment
* Human pharmacology of SPM 927
* 'First in patient' evaluation- where can improvements be made?
* Efficacy and tolerability in diabetic neuropathy
* Efficacy in other indications
Dr. Christine Rauschkolb
Program Director/ Medical Scientist Pain- Clinical Development
Schwarz BioSciences
11:00 Morning Coffee
11:20 NAALADase Inhibition: a Novel Mechanism for Treating Neuropathic Pain and Peripheral Neuropathy
* Selective Blockade of excitotoxic glutamate
* Efficacy in multiple animal models of peripheral neuropathy, neuropathic pain, stroke, and ALS
* Phase 1 trial results
Krystyna Wozniak
Lead Scientist on NAALADase Program
Guilford Pharmaceutical Inc
HEADACHE AND MIGRAINE PAIN- PRODUCT ANALYSIS
VIOXX - First Coxib Approved of Acute Migraine
* Migraine - a serious debilitating disorder
* Current acute migraine therapy
* Efficacy of rofecoxib in acute migraine therapy
* Safety of rofecoxib in acute migraine therapy
* Role of rofecoxib in acute migraine therapy
Dr. Tony Ho
Associate Director
Merck
12:40 Lunch
MARKET OPPORTUNITIES
14:00 CASE STUDY: The NanoCrystal Technology Approach
* How to overcome solubility issues for pain therapeutics
* Technology performance advantages
* Can it be used as a life cycle management tool?
* A commercialised, validated solution
Gary Liversidge
Senior Director, Project Planning and Management
Elan
14:40 CASE STUDY: Peptrans, a Novel Approach to Brain
Delivery
* The BBB and drug delivery in the CNS
* Pep:trans mechanism of action
* Delivery of analgesics- an effective solution?
* Potential within the market- where can you capture a share of
the market?
Jamal Temsamani
Director, Preclinical R&D
Synt:em
15:20 Afternoon Tea
15:40 Cannabis Based Medicines- How to Optimise Pain
Treatment
* Clinical indication and pain management with cannabinoids
* GW cultivation license, possession and supply for medical
research
* R&D clinical trials- quality, safety, efficacy and phase I-III trials
* Drug delivery technologies- oro mucosal sprays, oral
formulations and inhalers
* Limitations of cannabinoid therapies- where can you fail?
* Case study: update on Sativex
Dr. Stephen Wright
Director of R&D
GW Pharma Ltd
16:20 Regulatory Limitations- Use and Distribution of Narcotic
Drugs
* Medical narcotics, the potential for misuse
* The prevention of drug abuse- new methods and control
* National drug policies- updates and how to enforce them
* Control of substances- how it limits availability for
legitimate use
Dr. Mike Reed
Director Branded Product Marketing International
Alpharma
17:00 Generics: Identifying and Overcoming the Legal and
Regulatory Challenges of the Future
* The latest developments affecting the generic drug sector and
pharmaceutical legislation
* Important legal issues- current scientific initiatives
* Potential solutions to current challenges
* Key regulatory issues in Europe
Mr. Horst Kastrup
VP Worldwide Regulatory Affairs
Viatris
17:40 Questions and Discussion
18:00 Chairman summation
18:10 Close of Conference
Terms & Conditions
NB - Due to high demand, we do not 'reserve' or 'hold' places - a request for an invoice to be raised will be treated as an official booking and will be subject to the cancellation policy as outlined below.
Cancellations/substitutions and name changes: All bookings carry a 50% liability after the booking has been made, by post fax, email or web. There will be no refunds for cancellations received on or after one month before the start of the conference (e.g. cancellation on or after 20th January for a conference starting on 20th February). If you decide to cancel after this date the full invoice remains payable. Conference notes, which are available on the day, will be sent to you. Unfortunately we are not able to transfer places between conferences and executive briefings. However if you are unable to attend the event you may make a substitution/name change at any time as long as we are informed in writing by e-mail, fax or post. Name changes and substitutions must be from the same company and are not transferable between companies or countries.
Indemnity: visiongain Ltd reserve the right to change the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to acts of terrorism, war, extreme weather conditions, industrial action, acts of God or any event beyond the control of visiongain Ltd. If such a situation arises we will endeavour to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or expenses, which may be incurred by the customer as a consequence of the event being postponed or cancelled. We therefore strongly advise all customers to take out insurance to cover the cost of the registration, travel and expenses.
To unsubscribe please reply with unsubscribe in the subject line.
Data protection: Visiongain Ltd gathers and manages data in accordance with the Data Protection Act 1998. Information contained about you may be used to update you on visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. If you wish your details to be amended, please send your request to the Database Manager, visiongain Ltd, 40 Tooting High Street, London, SW17 0RG. Alternatively please reply with unsubscribe in the subject line. Please allow approximately 7 days for your removal or update request, you may receive additional pieces of communication from visiongain Ltd during the transitional period, whilst the changes come into effect.
#####################################################################################
This email has been scanned by MailMarshal, an email content filter.
#####################################################################################
Due to multiple requests and following the Globecom 2004 guidelines we are
extending the deadline to JULY 15th 2004.
1st IEEE International Workshop on Networking Issues in Multimedia
Entertainment (NIME'04)
CALL FOR PAPER AT: http://nime04.csr.unibo.it/nime04
IEEE Workshop @ GLOBECOM 2004
November 29th 2004
Dallas, TX, USA
EXTENDED SUBMISSION DEADLINE July 15th 2004.
The papers accepted will be published in the workshop proceedings (by IEEE)
and made available on line through IEEE-Explorer.
Our Sincere apologies if you receive multiple copies.
Regards
Giovanni Pau, Marco Roccetti & S.S. Lee
========================================
"... Loving might be a mistake but it's worth making
Don't let some hell bent heart leave you bitter ..."
(Lee Ann Woomak - I hope you dance)
========================================
Giovanni Pau, PhD
UCLA - Computer Science Department
3803A BH, Boelter Hall
Los Angeles, 90095 CA
Ph: (310) - 206-3212; Cell: (310) - 617-4728
Fax: (310)- 825-7578
http://www.cs.ucla.edu/~gpau
Dear all,
please find enclosed the minutes of meeting 2004/1 in Athens
(May 14+15, Athens),
Thanks once again to:
- Ioannis Stavrakakis for the perfect organisation of the meeting
- Peter Radford for the careful writing of the meeting minutes.
Best regards
Otto
Dear all,
you will remember from the discussions in Athens and/or
from the minutes that we have to use at least 20 percent of the
TC6 fund per year (which is above a threshold value of 15.000 EURO)
or the non used part will be capped and put into the global budget
of IFIP. Expenditures of this kind are for student travel, best paper
awards, tutorial speaker's cost etc, *not* for operational expenses.
According to the allocations of the past + some new requests (which
sometimes came quite unexpectedly and which will have to be
approved at our meeting 2004/2 in Bangkok!)
I have submitted a request for 22.500 EURO (+5.000 EURO for
operational expenses). This is well above our minimum of 13.000 EURO
and it is questionable whether TC6 can continue to spend so much
money every year.
Please find below a list of requests together with some explanations.
Best regards
Otto
----------------------------------
----------------------------------
Event funded requests of TC6 for 2005:
IFIP TC6 requests a budget of 27.500 EURO for 2005.
This is split up into (see below):
- student travel grants 12.500 EURO
- best paper awards 6.000 EURO
- tutorial speakers cost 4.000 EURO
- operational expenses 5.000 EURO
The fund balance of TC6 was roughly 80.000 EURO,
i.e. 65.000 EURO above the threshold of 15.000 EURO.
We have to use at least 20 percent of that fund, i.e.
13.000 EURO, for nonoperational expenses.
The planned expenditure of 27.500 - 5.000 = 22.500 EURO
is well above the lower limit of 13.000 EURO.
----------------------------------------
Use of the budget:
Student travel grants Best paper awards
(750 EURO each) (500 EURO each)
WG 6.1: Middleware: 2 (= 1.500 EURO) 1 (= 500 EURO)
FORTE 1 (= 750 EURO) 1 (= 500 EURO)
TESTCOM 1 (= 750 EURO) 1 (= 500 EURO)
WG 6.2: Networking 2 (= 1.500 EURO) 1 (= 500 EURO)
MWCN 1 (= 500 EURO)
WG 6.4: WWW 3 (= 2.250 EURO) 1 (= 500 EURO)
WG 6.6: IM 2005 2 (= 1.500 EURO) 1 (= 500 EURO)
NOMS 2 (= 1.500 EURO) 1 (= 500 EURO)
MMNS 1 (= 500 EURO)
DSOM 1 (= 500 EURO)
WG 6.8: PWC 2 (= 1.500 EURO) 1 (= 500 EURO)
WG 6.10: ONDM 2 (= 1.500 EURO) 1 (= 500 EURO)
Subtotal: 12.750 EURO 6.000 EURO
WG 6.9: Request of 4.000 EURO for tutorialists travel
to LANC 2005 in Cali (Colombia)
Operational Expenses: 5.000 EURO
Total (Event funded expenses + tutorial speaker cost +
Operational expenses)
27.750 EURO
This is higher than the budget planned for 2004 (which was 25.000 EURO).
The reasons:
- NOMS was forgotten but got the funds promise in 2004.
- WWW got a higher promise than indicated in the meeting minutes
of meeting 2003/2 (3 student travels instead as 2)
- ONDM came recently ?in a fully unexpected way"
with a request of 2 student grants + 1 PBA.
On the other hand some conferences of 2004 will not be hold in 2005
(INTELLCOMM,...) and thus student travels + tutorial speakers cost were
not claimed for 2005.
However, we cannot exclude that some additional requests are still
to come.
In the future it will have to be discussed whether we can afford such a
high amount of cost; especially the student travel cost might be reduced.
To my opinion, a conference should return to TC6 at least the cost which
it claims from TC6 for support.
A positive example of that was NOMS'94 which got 2.000 EURO
(see above) but which returned 6.300 EURO to IFIP.
The allocation is preliminary! In Bangkok we will have to decide whether
we accept the new request from ONDM, the increased claim
for WWW etc.